KELOWNA, BC / ACCESS Newswire / April 29, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (&#34;Lexaria&#34; or the &#34;Company&#34;), a global innovator in oral drug delivery platforms, provides this update on the Material Transfer

<p><strong id="dateline">KELOWNA, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / April 29, 2026 / </strong>Lexaria Bioscience Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/LEXX">LEXX</a>) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on the Material Transfer Agreement ("MTA") originally entered into on August 30, 2024 with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's DehydraTECH<sup>&#8482; </sup>technology in a pre-clinical setting.</p><p>The <a rel="nofollow" href="https://pr.report/l4o0">original agreement</a> has been successfully extended through December 31, 2026, to accommodate time required for PharmaCO's receipt and review of Lexaria's 2026 research & development ("R&D") results related to GLP-1. This allows the two parties to continue their relationship under the MTA, keep the temporary exclusive license active and in force, and contemplate additional strategic planning discussions with PharmaCO's human clinical and business development teams.</p><p>Over the past 12 months, Lexaria has taken important steps in advancing its GLP-1 development program. This includes recently announced progress in each of its 2026 R&D studies: <a rel="nofollow" href="https://pr.report/l4o1">Human Study #7</a>; <a rel="nofollow" href="https://pr.report/l4o2">Animal Study #1</a>; and <a rel="nofollow" href="https://pr.report/l4o3">Animal Study #2</a>. All of these studies are within the GLP-1 sector and have been designed with the goal of providing fulsome evidence to better allow additional collaboration and potential licensing of Lexaria's technology.</p><p>Each of the studies mentioned above are in process and are fully funded with existing corporate resources. Results are expected during Q3 and Q4 of this calendar year.</p><p><strong>About Lexaria Bioscience Corp. & DehydraTECH</strong></p><p>DehydraTECH<sup>&#8482;</sup> is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit <a rel="nofollow" href="https://pr.report/l4o4">www.lexariabioscience.com</a>.</p><p><strong>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</strong></p><p>This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</p><p><strong>INVESTOR CONTACT:</strong></p><p><strong>George Jurcic - Head of Investor Relations</strong><br/><a rel="nofollow" href="mailto:ir@lexariabioscience.com">ir@lexariabioscience.com</a><br/>Phone: 250-765-6424, ext 202</p><p><strong>SOURCE:</strong> Lexaria Bioscience Corp.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/consumer-and-retail-products/material-transfer-agreement-between-pharmaceutical-company-and-lexaria-1162287'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1162287" width="0" height="0"/>

LEXX

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Lexaria Extends PharmaCO Partnership to Advance GLP-1 Development

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>KELOWNA, BC / ACCESS Newswire / April 29, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (&amp;#34;Lexaria&amp;#34; or the &amp;#34;Company&amp;#34;), a global innovator in oral drug delivery platforms, provides this update on the Material Transfer</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Lexaria Bioscience extended its Material Transfer Agreement with PharmaCO to December 2026, focusing on its DehydraTECH technology for GLP-1 development. Results from ongoing studies are anticipated in Q3 and Q4, which could bolster collaboration and licensing opportunities, impacting the company&#039;s future revenue prospects.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Lexaria extended its collaboration with PharmaCO through December 2026.</li><li>The collaboration focuses on Lexaria&#039;s DehydraTECH technology and GLP-1 development.</li><li>Results from ongoing GLP-1 studies are expected in Q3 and Q4 2026.</li><li>Lexaria&#039;s intellectual property includes 65 patents, strengthening its market position.</li><li>The company is fully funding its current studies with existing resources.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>PharmaCO</strong>: Ongoing partnership indicates confidence in Lexaria&#039;s technology.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news falls under &#039;Corporate Developments&#039; as it pertains to Lexaria&#039;s strategic partnership extension with PharmaCO, which is essential for their product advancement and potential revenue generation.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Successful R&amp;D outcomes may lead to new partnerships or licensing deals.</li><li>Extension of MTA shows PharmaCO&#039;s ongoing commitment to Lexaria&#039;s technology.</li><li>Investors should monitor the release schedule for study results.</li><li>Potential regulatory approvals could significantly boost market perception.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Agreement with PharmaCO extended to December 31, 2026.</li><li>Research results expected in Q3 and Q4 2026.</li><li>Lexaria holds 65 granted patents and pending patents worldwide.</li><li>DehydraTECH aims to enhance drug delivery through oral methods.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>LEXX is likely to see upward momentum as study results arrive in late 2026.</p>
  </section>
</section>


<p><strong id="dateline">KELOWNA, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / April 29, 2026 / </strong>Lexaria Bioscience Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/LEXX">LEXX</a>) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on the Material Transfer Agreement ("MTA") originally entered into on August 30, 2024 with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's DehydraTECH<sup>&#8482; </sup>technology in a pre-clinical setting.</p><p>The <a rel="nofollow" href="https://pr.report/l4o0">original agreement</a> has been successfully extended through December 31, 2026, to accommodate time required for PharmaCO's receipt and review of Lexaria's 2026 research & development ("R&D") results related to GLP-1. This allows the two parties to continue their relationship under the MTA, keep the temporary exclusive license active and in force, and contemplate additional strategic planning discussions with PharmaCO's human clinical and business development teams.</p><p>Over the past 12 months, Lexaria has taken important steps in advancing its GLP-1 development program. This includes recently announced progress in each of its 2026 R&D studies: <a rel="nofollow" href="https://pr.report/l4o1">Human Study #7</a>; <a rel="nofollow" href="https://pr.report/l4o2">Animal Study #1</a>; and <a rel="nofollow" href="https://pr.report/l4o3">Animal Study #2</a>. All of these studies are within the GLP-1 sector and have been designed with the goal of providing fulsome evidence to better allow additional collaboration and potential licensing of Lexaria's technology.</p><p>Each of the studies mentioned above are in process and are fully funded with existing corporate resources. Results are expected during Q3 and Q4 of this calendar year.</p><p><strong>About Lexaria Bioscience Corp. & DehydraTECH</strong></p><p>DehydraTECH<sup>&#8482;</sup> is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit <a rel="nofollow" href="https://pr.report/l4o4">www.lexariabioscience.com</a>.</p><p><strong>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</strong></p><p>This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</p><p><strong>INVESTOR CONTACT:</strong></p><p><strong>George Jurcic - Head of Investor Relations</strong><br/><a rel="nofollow" href="mailto:ir@lexariabioscience.com">ir@lexariabioscience.com</a><br/>Phone: 250-765-6424, ext 202</p><p><strong>SOURCE:</strong> Lexaria Bioscience Corp.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/consumer-and-retail-products/material-transfer-agreement-between-pharmaceutical-company-and-lexaria-1162287'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1162287" width="0" height="0"/>

Lexaria Bioscience extended its Material Transfer Agreement with PharmaCO to December 2026, focusing on its DehydraTECH technology for GLP-1 development. Results from ongoing studies are anticipated in Q3 and Q4, which could bolster collaboration and licensing opportunities, impacting the company's future revenue prospects.

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News